Advanced Cancer clinical trials in California

Studying MOMA-313 for advanced or metastatic solid tumors

This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.

Tracking how larotrectinib works for NTRK fusion cancers in routine care

This study follows people with cancers that have an NTRK gene fusion to learn how safe and effective larotrectinib is during everyday treatment. It may help confirm whether this medicine works well in real-world patients and side effects stay manageable.

Adding chemo or immunotherapy before surgery for advanced head and neck cancer

This trial tests whether giving chemotherapy or chemotherapy plus immunotherapy before surgery can improve outcomes for people with advanced head and neck cancer that has come back or not gone away after prior treatment.

Testing a new treatment for pancreatic cancer before surgery

This trial tests a new treatment, PTM-101, placed during a laparoscopy procedure for people with pancreatic cancer that can be removed with surgery. It aims to see if adding this treatment before standard chemotherapy helps improve outcomes.

Testing BAY 3771249 for Advanced Colorectal Cancer With KRAS Mutation

This early-stage study tests a new drug called BAY 3771249 in people with advanced colorectal cancer that has a specific genetic change (KRAS G12D mutation). Researchers want to learn if it's safe and whether it helps shrink tumors.

Low-dose doxorubicin plus peposertib for advanced sarcoma

This Phase 1 trial tests a low dose of a common chemotherapy (liposomal doxorubicin) together with an anti-cancer drug called peposertib. It’s for people with advanced sarcoma that can’t be cured, aiming to find a safe dosing plan and see how well the treatment might work.

Testing a new targeted drug for advanced solid tumors with PI3Kα mutation

This trial tests tersolisib, a new targeted medicine, in adults with advanced or hard-to-remove solid cancers. It focuses on tumors that have a specific genetic change (PI3Kα mutation) to see how well the treatment works and what side effects it causes.

Study of MBRC-101 for advanced solid tumors

This trial tests a new drug, MBRC-101, that targets a protein called EphA5 found on some cancer cells. It is for people with advanced solid tumors (like lung, breast, or pancreatic cancer) that have stopped responding to other treatments. The study aims to find a safe dose and see if the drug can shrink tumors.

Study of new drugs for HR+/HER2- advanced breast cancer

This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.

Testing T-DXd combinations for HER2 stomach or esophagus cancer

This Phase 2 study tests how safe and effective T-DXd (an anti-cancer medicine) is in combination for people with advanced stomach/GEJ/esophagus cancer that is HER2-positive or HER2-low. It may help people whose cancer has spread or cannot be removed, depending on their prior treatments and test results.

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

HER3-DXd for advanced solid tumors after prior treatment

This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.

Studying AZD0901 for Claudin18.2-positive advanced solid tumors

This trial tests a new drug called AZD0901 for people with advanced solid tumors that have a specific protein on their surface. It aims to see if the drug can shrink or slow the growth of these tumors.

Test drug RMC-6236 for certain RAS mutations in advanced cancers

This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.

Study T-cell therapy for advanced liver cancer

This trial tests a custom immune-cell treatment made to target a marker (GPC3) found on some liver cancers. It’s for adults with advanced HCC whose cancer has worsened after standard treatment or who couldn’t tolerate it.

Testing ARX788 for HER2-low advanced breast cancer

This trial tests a new drug, ARX788, for people with HER2-low breast cancer that has spread or cannot be removed by surgery. The goal is to see if ARX788 helps shrink or control the cancer.

A study of T-DXd and rilvegostomig for HER2-positive bile duct cancer

This trial tests a new combination of two drugs (T-DXd and rilvegostomig) for people with advanced bile duct cancer that has not been treated before. The cancer must have high levels of a protein called HER2. This study compares the new drugs to standard treatments.

Study of RMC-9805 for KRAS G12D solid tumors

This trial tests an experimental pill (RMC-9805) for people with solid tumors that have a specific KRAS G12D mutation. It's for those who have already tried other treatments and need new options.

Zanidatamab plus chemo for advanced HER2-positive bile duct cancer

This phase 3 trial tests whether adding zanidatamab (a targeted antibody) to standard chemotherapy can improve outcomes for advanced HER2-positive biliary tract cancer. If you have this type of cancer that has spread or can't be removed, and you've had little or no prior treatment, this study might be an option.

Testing a new drug combo for advanced breast cancer or melanoma

This trial tests a new combination of drugs (AMXT 1501, DFMO, and standard therapies) for people with advanced solid tumors, specifically breast cancer (ER+ HER2-) or melanoma that has progressed after other treatments. The goal is to see if this combination can help shrink tumors or slow their growth.

Drug TT-10 and TT-4 for advanced solid tumors

This early-phase trial tests two investigational drugs—TT-10 and TT-4—alone and together in people with advanced solid cancers. The study is designed to find safe doses and see if the treatment can shrink tumors or slow cancer growth.

Sotorasib and trastuzumab deruxtecan for KRAS G12C lung cancer

This trial tests a combination of two drugs, sotorasib and trastuzumab deruxtecan, for people with advanced or metastatic non-small cell lung cancer that has a KRAS G12C mutation. It may be an option if you've already had treatment with a KRAS G12C inhibitor, immunotherapy, and chemotherapy.

Study of a new drug for advanced liver cancer

This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.

Divarasib for untreated lung cancer with KRAS G12C

This trial studies divarasib to see if it is safe and can shrink or control advanced lung cancer. Participants must have a KRAS G12C mutation and have not had prior treatment for their advanced disease.